Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE:DNA
Want to see DNA full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.05Last Year’s EPS
-1.1Same Quarter Last Year
Moderate Sell
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a balanced picture: meaningful operational and strategic progress in autonomous labs (Nebula), AI-driven experiments, partnerships and a strong cash position, alongside significant near-term financial challenges including a sharp revenue decline, ongoing losses, negative adjusted EBITDA and cash costs from excess leases and one-time payments. Execution and commercialization of Nebula, cloud lab and channel partnerships will determine whether the recent technical and commercial wins translate into durable revenue growth.Company Guidance
Strong Cash Position and No Debt
Cash balance of $373 million with no bank debt as of Q1 2026, providing runway to invest in autonomous labs and related initiatives.
Material Reduction in Operating Costs
R&D expense decreased 38% (from $49M to $30M) and G&A expense decreased 35% (from $20M to $13M) year-over-year, driven by restructuring; net loss from continuing operations improved to $76M from $83M.
Improved Cash Burn and Reaffirmed 2026 Guidance
Q1 2026 cash burn was $48M, down 17% from $58M in Q1 2025; company reaffirmed full-year 2026 cash burn guidance of $125M–$150M.
Autonomous Lab (Nebula) Expansion and Usage
Nebula expanded from ~50 racks to a planned 103–105 racks, ran 100+ protocols (30+ unique), integrated 80+ devices, and had a peak day with ~439 scientists submitting protocols, demonstrating scale and customer engagement.
Revenue-Generating Contracts & Strategic Spin-Off
Signed a $47M contract with Pacific Northwest National Labs for a large autonomous lab deployment; closed the biosecurity spin-off (Perimeter) raising $60M and positioning Ginkgo as a shareholder.
AI Integration Demonstrated with OpenAI
OpenAI project using GPT-5 to design experiments achieved a 40% improvement in the cost of cell-free protein synthesis over scientific state-of-the-art after 6 design rounds, validating AI-driven experimental workflows.
Cloud Lab, DataPoints and Channel Partnerships
Launched cloud.ginkgo.bio (cloud lab) with multiple protocols posted and price transparency; DataPoints onboarded 10 top biopharma customers in its first year; new channel partnerships announced with AWS (Amazon BioDiscovery), Benchling and Tamarind Bio.
DNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $10.32 | $8.93 | -13.47% |
Feb 26, 2026 | $9.71 | $6.75 | -30.48% |
Nov 06, 2025 | $11.30 | $8.95 | -20.80% |
Aug 07, 2025 | $13.46 | $12.29 | -8.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ginkgo Bioworks Holdings, Inc. (DNA) report earnings?
Ginkgo Bioworks Holdings, Inc. (DNA) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Ginkgo Bioworks Holdings, Inc. (DNA) earnings time?
Ginkgo Bioworks Holdings, Inc. (DNA) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DNA EPS forecast?
DNA EPS forecast for the fiscal quarter 2026 (Q2) is -1.05.
